Christine Alewine

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Venues

Cancer research

Molecular cancer research : MCR

Future oncology (London, England)

Cancers

NIH/ National Cancer Institute

University of Maryland School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

NIH/ National Cancer Institute

United States

Investigator :: Center for Cancer Research

NIH/ National Cancer Institute

United States

Assistant Clinical Investigator :: Center for Cancer Research

Education History

University of Maryland School of Medicine

United States

PHD :: Physiology

Publications

Christine Alewine
Macrophages Under the Influence of Tumor Mesothelin Weaken Host Defenses against Pancreatic Cancer Metastasis. Cancer research 84 (4) (2024)
Christine Alewine
Macrophages Under the Influence of Tumor Mesothelin Weaken Host Defenses against Pancreatic Cancer Metastasis. Cancer research 84 (4) (2024)
Christine Alewine
Macrophages Under the Influence of Tumor Mesothelin Weaken Host Defenses against Pancreatic Cancer Metastasis. Cancer research 84 (4) (2024)
Nebojsa Skorupan, Mayrel Palestino Dominguez, Samuel L Ricci, Christine Alewine
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers 14 (17) (2022)
Guillaume Joe Pegna, Min-Jung Lee, Cody J Peer, Mehwish I Ahmad, David J Venzon, Yunkai Yu, Akira Yuno, Seth M Steinberg, Liang Cao, William D Figg, Renee N Donahue, Raffit Hassan, Ira Pastan, Jane B Trepel, Christine Alewine
Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel. Cancer medicine (2022)
Nebojsa Skorupan, Mehwish I Ahmad, Seth M Steinberg, Jane B Trepel, Derek Cridebring, Haiyong Han, Daniel D Von Hoff, Christine Alewine
A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas. Future oncology (London, England) 18 (20) (2022)
Brendan Hagerty, T Norene O'Sullivan, Xianyu Zhang, N Keith Collins, Wendi Custer Lawrence, Laura L Bassel, Nathan M Pate, Jian Xu, Theresa M Guerin, Serguei Kozlov, Christine Alewine
Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Molecular cancer therapeutics 20 (10) (2021)
Qun Jiang, Azam Ghafoor, Idrees Mian, Daniel Rathkey, Anish Thomas, Christine Alewine, Manjistha Sengupta, Mark A Ahlman, Jingli Zhang, Betsy Morrow, Seth M Steinberg, Ira H Pastan, Raffit Hassan
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Science translational medicine 12 (550) (2021)
Jian Xu, Mayrel Palestino Dominguez, Christine Alewine
Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci. Cancer communications (London, England) (2021)
Leela Rani Avula, Brendan L Hagerty, Christine Alewine
Molecular mediators of peritoneal metastasis in pancreatic cancer. Cancer metastasis reviews 39 (4) (2020)
Leela Rani Avula, Michael Rudloff, Salma El-Behaedi, Danielle Arons, Rakan Albalawy, Xiongfong Chen, Xianyu Zhang, Christine Alewine
Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases. Molecular cancer research : MCR 18 (2) (2019)
Salma El-Behaedi, Rebekah Landsman, Michael Rudloff, Emily Kolyvas, Rakan Albalawy, Xianyu Zhang, Tapan Bera, Keith Collins, Serguei Kozlov, Christine Alewine
Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors. Toxins 10 (11) (2018)

Christine Alewine.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Christine Alewine